Recurium IP Holdings, LLC

Immunome, Inc.

Kalyra Pharmaceuticals, Inc.

Zeno Royalties & Milestones, LLC

Pharmakea, Inc.

Recurium IP Holding, LLC

Zeno Management, Inc.

Kevin Duane Bunker

Peter Qinhua Huang

Joseph Robert Pinchman

Chad Daniel Hopkins

Deborah Helen Slee

Rakesh Kumar Sit

Mehmet Kahraman

Sunny Abraham

Sayee Gajanan Hegde

Ahmed Abdi Samatar

Suvi Tuula Marjukka Orr

Kimberlee Fischer

Xiaojun Han

Brant Clayton Boren

Aditya Krishnan Unni

Sunil Paliwal

Guobao Zhang

Daniel Lee Severance

Hui Liu

Chuangxing Guo

Mark Charles Grier

John Howard Hutchinson

David Gregory Lonergan

Benjamin Pratt

Timothy Andrew Parr

Fernando Donate

Yuanqing Fang

Matthew M Bio

Qinhua Huang

Jiali Li

Andrew M Clausen

Jianhui Ma

Sobhana Babu Boga

Hui Li

Jillian W Sheeran

Christopher Breen

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

Benzamide compounds

Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tertiary alcohols can be used to prepare synthetic versions of natural products and/or pharmaceuticals.

Chiral synthesis of a tertiary alcohol

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.Ab-[S-L-L-L-L-L-L-L-D]   (I)

Immunoconjugates and methods

Disclosed herein are nitrogen-containing bicyclic compounds of Formula (I), including pharmaceutically acceptable salts thereof, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR inhibitor compounds

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.

Estrogen receptor modulators

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.Ab-[S-L-L-L-L-L-L-L-D]&#x2003;&#x2003;(I)

Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.

Process for making [1.1.1]propellane

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV. 

Growing community of inventors

Escondido, CA, United States of America

Kevin Duane Bunker